Incannex terminates $108.4M ATM sales agreement; announces enhanced Phase 2 dose-optimisation study

Incannex Healthcare Inc.

Mutually terminated Sales Agreement with Curvature Securities and A.G.P., effective March 11, 2026.
Raised aggregate gross proceeds of ~$108.4M under the agreement prior to termination.
Issued press release announcing enhanced Phase 2 dose-optimisation study (likely IHL-42X for OSA).
Corporate presentation confirms cash position of ~$70M as of December 2025.
Pipeline includes Phase 2/3 trials for OSA, GAD, and RA with positive data reported August 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Incannex Healthcare Inc. terminated Sales Agreement with Curvature Securities, LLC and A.G.P./Alliance Global Partners valued at Aggregate gross proceeds of approximately $108.4 million; termination at will with no penalty (effective 2026-03-11).

Action: termination
Agreement: atm program
Counterparty: Curvature Securities, LLC and A.G.P./Alliance Global Partners
Value: Aggregate gross proceeds of approximately $108.4 million; termination at will with no penalty
Effective: 2026-03-11

Exact text from the filing

On March 11, 2026, the Company and the Sales Agents mutually agreed to terminate the Sales Agreement, effective immediately.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Incannex Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-026644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.